Clinical trial
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In…
NCT00338884 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00338884 |
|---|---|
| Title | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer |
| Official title | A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sunitinib malate |
| Enrollment | 120 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jun 20, 2006 |
| Last update posted | Aug 31, 2012 |
| Countries | Argentina, Australia, Brazil, Mexico, South Korea, Taiwan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: